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0959-8049/ª 2019 Elsevier Ltd. All righAbstract Background: The process of social, political and economic transformation, which
took place in Central and Eastern Europe in the early 90’s, has affected many spheres of Eu-
ropeans’ lives, including health-associated issues. These changes also had an impact on mor-
tality rates due to cervical cancer (CC). Therefore, the aim of this study was to analyse CC
mortality trends in Europe after 1990.
Methods: Data on death due to CC, uterine cancers and unspecified uterine cancers, in women
aged 20e44, were taken from the WHO Mortality Database. Trends in European countries
between 1990 and 2017 were assessed using the Joinpoint Regression Program.
Results: Most of the countries experienced a decrease inCCmortality. Although the lowest rates
were observed in EU15 Member States, the highest decreases were observed in Central and
EasternEurope.However, there are still differences inmortality in these countries. There are also
a few countries likeBelarus, Latvia andUkraine, which experienced an increase inmortality. The
range of mortality across Europe in 2017 was between 0.6 and 5.2/100,000 women.
Conclusions: It is essential to introduce well-organised screening programmes for early detection
of CC with coverage of a correspondingly high percentage of the population, particularly in East-
Central Europe, as well as to introduce high-coverage HPV vaccination in all European countries.
ª 2019 Elsevier Ltd. All rights reserved.Prevention Research Institute e Collaborating Centre, State University of Applied Sciences, Nowy Swiat 4
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Every year in Europe, more than 60,000 new cervical
cancer (CC) cases are diagnosed and over 25,000 women
die from the disease [1]. This makes it the second most
common cancer in women aged 15e44 years [1].
Standardised incidence rate of CC in Europe averages at
11.2/100,000 women and standardised mortality rate at
3.8/100,000 women.
After the Second World War, East-Central Europe
was incorporated into the so-called Eastern Bloc and the
Soviet Union sphere of influence. Its countries had
planned and centralised economy, and many aspects of
the social life were controlled by the state. Health care
was free and was provided to all citizens. The Soviet
Union collapse began in 1989. Political, economic and
social changes took place in Europe, which influenced
health policy of particularly the so-called transitional
countries [2]. These are countries of the former
communist states in Europe after collapse of the “Iron
Curtain” in 1989e1990 (Estonia, Latvia, Lithuania,
Czech Republic, Slovakia, Poland, Hungary, Slovenia,
Romania, Bulgaria, Croatia, Albania, Bosnia and Her-
zegovina, Macedonia, Montenegro, Serbia, Belarus,
Moldova and Ukraine), which experienced major po-
litical, economic, social and epidemiological changes
[3e5]. Later, these countries formed independent gov-
ernments and began to lead their own, independent
policies, also regarding health care systems. However,
they were struggling with insufficient financial resources
and, therefore, in many cases, health care was no longer
free and was not provided to all citizens. After 1990,
most of these countries began to introduce organised
programmes for prevention of CC. Implementing such
programmes on a national level is the only way to
eliminate CC, and from the standpoint of public health,
elimination of CC means mortality below 1/100,000
women in a given population [6,7].
Levi et al. [8] analysed CC mortality in women aged
20e44 in Europe over the period between 1960 and
1998. The reason for the choice of this age group was a
difference in the classification of uterine tumours be-
tween individual countries. It was difficult to present a
reliable analysis concerning the analysed years, because
it was impossible to distinguish between cervical and
corpus uteri cancers based on death certifications.
Several deaths were attributed to unspecified uterine
cancer and its percentage differed significantly
comparing particular countries and particular years of
observation in a given country [8]. To avoid classifica-
tion bias, authors decided to present mortality rates
from CC, cancer of corpus uteri and unspecified uterine
cancer as a single group, only among women under 45.
The reason was that the majority of death causes due to
uterine cancers, among women in this age group, is
caused by CC [8,9]. Mentioned differences in theclassification of reproductive organ tumours between
individual countries are still present.
The aim of the study was to continue the observation
of Levi et al. and analyse CC mortality rates and trends
in 20e44 years old women in European countries and to
examine changes that have occurred in the epidemiology
of the disease after 1990.
2. Materials and methods
We carried out an analysis of trends in CC mortality
among women aged 20e44 between 1990 (or in the first
year after 1990 for which data were available) and 2017
(or in the last year before 2017 for which data were
available) in selected European countries. In addition to
the European Union (EU) Member States, the situation
was also analysed in the European transitional coun-
tries, because this group was expected to show the
biggest changes in trends, due to political trans-
formations, which took place after 1990. We excluded
Bosnia and Herzegovina, Montenegro, Cyprus, Malta
and Luxembourg from this analysis because of small
numbers of deaths.
Data on death due to CC together with uterine can-
cers and unspecified uterine cancers were taken from the
World Health Organization (WHO) Mortality Data-
base. This database provides information concerning the
number of deaths by causes defined in the International
Classification of Diseases (ICD), according to gender,
age and calendar year. The analysis included deaths as
specified in the ICD-9 by number 180, 179 and 182 and
in ICD-10 by code C53, C54 and C55. Standardised
mortality rates expressed per 100,000 women were
calculated using world standard population [10]. No
extrapolation was made for the missing data.
In the majority of the selected countries, data were
available for the period 1990e2014, e2015, e2016 or
e2017 (Table 2), with the exception of Serbia, for which
data were available since 1998. There was lack of some
data for Belarus, Poland, Portugal, Slovakia, Ukraine
and United Kingdom. Probably this type of data has not
been provided by relevant national organizations.
The analysis of CC mortality trends in European
countries was performed using Joinpoint Regression
Analysis (Joinpoint Trends Analysis Software, version
4.5.0.1 [11]). This software allowed for the testing of
whether time trend changes within the studied time in-
terval were significant (p < 0.05). The maximum number
of joinpoints was set at three in each analysis. The best-
fit model was chosen with the statistically significant
Annual Percentage Changes (APC). APC between two
joinpoints are shown in the diagrams of individual
countries. In addition, we calculated the average APC
between 1990 and 2017.
The following terms: EU15 Member States (member
countries in the European Union before 2004) and
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for the purpose of this analysis.
3. Results
Table 1 presents the absolute number of deaths due to
CC, uterine cancer and unspecified uterine cancer
among women aged 20e44 in selected European coun-
tries at the beginning and at the end of the observation.
Initially, the percentage of uterine cancers located
outside the cervix ranged between 2.1% in the
Netherlands and 77.8% in Albania. In the last year ofTable 1
Number of deaths due to CC, uterine cancer and unspecified uterine
cancer and percent of other than cervical parts of uterus on all uterine
cancers among women aged 20e44 in selected European countries at
the beginning and at the end of the observation, 1990a and 2017b.
Country Number of deaths in
1990a
Number of deaths in
2017b
Cervical
cancer
Corpus and
unspecified
uterine
cancer (%)
Cervical
cancer
Corpus and
unspecified
uterine
cancer (%)
Albania (Alb) 2 7 (77.8) 1 2 (66.7)
Austria (Aus) 18 21 (53.8) 7 2 (22.2)
Belarus (Bela) 39 13 (25.0) 78 12 (13.3)
Belgium (Bel) 24 9 (27.3) 16 8 (33.3)
Bulgaria (Bul) 67 39 (36.8) 53 18 (25.4)
Croatia (Cro) 19 7 (26.9) 9 1 (10.0)
Czech Republic
(Cze)
87 21 (19.4) 37 7 (15.9)
Denmark (Den) 20 1 (4.8) 15 1 (6.3)
Estonia (Est) 13 7 (35) 6 0 (0.0)
Finland (Fin) 3 1 (25) 8 4 (33.3)
France (Fra) 133 82 (38.1) 78 38 (32.8)
Germany (Ger) 365 55 (13.1) 141 30 (17.5)
Greece (Gre) 13 21 (61.8) 17 7 (29.2)
Hungary (Hun) 110 14 (11.3) 48 10 (17.2)
Ireland (Ire) 16 1 (5.9) 25 1 (3.8)
Italy (Ita) 63 124 (66.3) 68 54 (44.3)
Latvia (Lat) 8 3 (27.3) 14 0 (0.0)
Lithuania (Lit) 31 4 (11.4) 15 3 (16.7)
Macedonia
(Mac)
2 3 (60.0) 5 5 (50.0%
Moldova (Mol) 24 12 (33.3) 33 3 (8.3)
Netherlands
(Net)
46 1 (2.1) 30 5 (14.3)
Poland (Pol) 388 56 (12.6) 90 18 (16.7)
Portugal (Por) 25 30 (54.5) 21 4 (16.0)
Romania (Rom) 338 63 (15.7) 154 27 (14.9)
Serbia (Ser) 73 24 (24.7) 56 5 (8.2)
Slovakia (Slo) 43 9 (17.3) 37 0 (0.0)
Slovenia (Sla) 12 4 (25.0) 5 0 (0.0)
Spain (Spa) 75 39 (34.2) 70 18 (20.5)
Sweden (Swe) 29 4 (12.1) 18 2 (10.0)
Ukraine (Ukr) 287 84 (22.6) 392 69 (15.0)
United Kingdom
(UK)
400 20 (4.8) 177 26 (12.8)
Total 2773 779 (21.9) 1724 380 (18.1)
a 1990 or first available year after 1990.
b 2017 or last available year before 2017.the observation, this percentage ranged from 0% in
Estonia, Latvia, Slovakia and Slovenia and 66.7% in
Albania. In addition, in particular countries the per-
centage changed over the analysed years, as in the case
of Greece, where it was almost 62% in 1990 and 29% in
2016.
Table 2 presents standardised mortality rates of
women due to CC and APC between the beginning and
the end of the observation. In 1990, higher CC mortality
rates were observed in Eastern European countries and
in Baltic States than in EU15 Member States. The
observed rates were in most of these cases above 3.5/Table 2
Cervical cancer mortality rates, Annual Percentage Change and data
availability, in the age group of 20e44 years.
Country Data
availability
(years)
Cervical cancer mortality rates
(per 100,000 women)
1990a 2017b Annual Percentage
Change between 1990a
and 2017b with
95% CI (%)
Northern Europe
Latvia (Lat) 1990e2015 2.08 3.81 2.4 (0.8; 4.0)
Lithuania (Lit) 1990e2017 4.97 3.57 0.7 (1.8; 0.4)
Ireland (Ire) 1990e2015 2.62 2.75 1.4 (2.5; 0.3)
Estonia (Est) 1990e2016 6.25 2.51 4.1 (5.6; 2.6)
United
Kingdom (UK)
1990e2016 3.78 1.75 3.0 (3.7; 2.3)
Denmark (Den) 1990e2015 1.99 1.58 3.3 (4.4; 2.2)
Finland (Fin) 1990e2016 0.4 1.31 2.1 (0.4; 3.9)
Sweden (Swe) 1990e2016 1.98 1.17 0.7 (1.9; 0.5)
Western Europe
Germany (Ger) 1990e2016 2.84 1.24 4.1 (4.6; 3.6)
Netherlands
(Net)
1990e2016 1.47 1.22 1.3 (2.0; 0.6)
Belgium (Bel) 1990e2016 1.67 1.18 1.9 (2.8; 0.9)
France (Fra) 1990e2015 1.79 1.0 2.1 (2.6; 1.6)
Austria (Aus) 1990e2017 2.68 0.55 5.0 (6.2; 3.8)
Eastern Europe
Ukraine (Ukr) 1990e2017 3.7 5.22 1.2 (0.6; 1.8)
Bulgaria (Bul) 1990e2015 6.0 5.05 0.5 (1.2; 0.1)
Belarus (Bela) 1990e2014 2.63 4.75 1.3 (0.7; 2.0)
Moldova (Mol) 1990e2017 4.33 4.7 0.3 (1.4; 0.8)
Romania (Rom) 1990e2017 9.37 4.53 3.3 (4.0; 2.6)
Slovakia (Slo) 1992e2014 4.59 3.19 3.2 (4.3; 2.0)
Hungary (Hun) 1990e2017 5.75 2.67 3.5 (4.2; 2.8)
Czech Republic (Cze) 1990e2017 4.99 1.94 3.3 (3.9; 2.7)
Poland (Pol) 1990e2016 5.47 1.38 5.0 (5.4; 4.6)
Southern Europe
Serbia (Ser) 1998e2016 6.2 4.52 2.2 (3.4; 1.0)
Macedonia
(Mac)
1991e2013 1.37 2.44 2.9 (5.1; 0.6)
Croatia (Cro) 1990e2016 2.79 1.33 2.5 (3.7; 1.3)
Portugal (Por) 1990e2016 2.91 1.25 3.8 (4.7; 2.9)
Slovenia (Sla) 1990e2015 3.86 1.23 4.5 (6.3; 2.7)
Greece (Gre) 1990e2016 1.8 1.13 2.3 (3.3; 1.2)
Italy (Ita) 1990e2015 1.67 1.02 2.3 (2.9; 1.8)
Spain (Spa) 1990e2016 1.6 0.87 2.4 (2.9; 1.9)
Albania (Alb) 1992e2010 1.67 0.56 2.5 (6.1; 1.2)
a 1990 or first available year after 1990.
b 2017 or last available year before 2017.
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region of Europe were in the range of 1.4e9.4/100,000
women. At that time, in most EU15 Member States, the
mortality rate did not exceed 2.7/100,000. The observed
rates were even lower in most of these countries at the
end of the observation, when the average mortality rate
was around 1/100,000. The situation also improved in
most of Baltic States as well as in Southern and Eastern
European countries, where the highest decreases in the
mortality rate were observed. However, this is a group of
countries, where we still observe differences in mortality
from CC, but the variety of rates is smaller than in 1990
(0.6e5.2/100,000 women). In this part of Europe, there
are countries which experienced a decrease in CC mor-
tality and achieved mortality rates around 2/100,000 in
2017, but there are also countries where the rate
remained around 4.5/100,000 (Romania Serbia, Bulgaria
and Moldova). There are also countries that experienced
increase in mortality rates, including Belarus, Latvia,
Ukraine and Finland. However, in Finland, we recorded
the mortality rate in 2017 to be around 1/100,000
women. Fig. 1 compares the APC in CC mortality
among young adult women between 1990 (or first
available) and 2017 (or last available) with the mortality
rate in 2017. With a few exceptions, the falls tended to be
greater in countries with originally higher rates.
Five different patterns of CC mortality trends were
observed (Fig. 2). The first one, observed in Austria,
Belgium, Croatia, Czech Republic, Denmark, Estonia,
France, Germany, Greece, Ireland, Netherlands,
Poland, Serbia, Slovakia, Slovenia and Spain, shows a
decrease throughout the observation period (A). The
second pattern (B), observed in Bulgaria, Hungary,
Lithuania, Macedonia, Moldova, Portugal, Romania
and Ukraine, was characterised by an increase in theFig. 1. Annual Percentage Change in cervical cancer mortality, in 20e
rate in 2017**.first phase and a decrease in the second phase of the
observation. The third pattern (C) was
first characterised by a decrease and then by an increase
and concerned Italy and the UK. The fourth pattern (D)
was recorded in Albania and Sweden and was charac-
terised with no changes in the mortality trend during the
observation. The last and unfavourable trend (E) was
characterised by a steady increase and concerned
Belarus and Latvia. Finland is one of the countries with
the lowest mortality due to CC. Additionally, there were
no joinpoints identified over the analysed period.
Therefore, Finland should be included in the group of
countries with constant mortality due to CC.
4. Discussion
Just like two decades ago, current classification of
deaths due to CC in particular countries in Europe is
problematic. After 1990, uterine cancer and unspecified
uterine cancer diagnoses among young adult women still
constitute a high percentage of all tumours of the uterus,
and their number often exceeds registered death cases
due to CC. To minimize classification bias, we analysed
deaths due to uterine cancers regardless of their
location.
Levi et al. noted a significant difference in CC mor-
tality between Western European countries, where the
mortality in the studied period decreased, and Eastern
European countries, where it grew. A significant in-
crease in the mortality in Eastern European countries
resulted from ineffective screening. In fact, the problem
was more complex, resulting from the changes in the
health care systems that occurred in late ‘80s in the
countries belonging to the former Eastern Bloc [12].
Remnants of these changes as well as the perception of44 years old women, between 1990* and 2017** and the mortality
Fig. 2. Cervical cancer mortality trends in 20e44 years old women in the European countries, 1990e2017.
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clinical medicine, survived in many Central and Eastern
European countries after the collapse of the Eastern
Bloc [2,13,14].
Epidemiological transition in this case refers to the
change in the pattern of CC mortality trend in women,
observed over a period of dozen years [15]. While ana-
lysing CC mortality trends of young adult women in
Europe over recent decades, the countries can be divided
into three groups, depending on the character of the
epidemiological transition of the disease. The first
group comprises countries where the epidemiological
transition of CC is completeddtheir CC mortality rate
is around 1/100,000 women [6,7]. This situation con-
cerns EU15 Member States, and Finland serves as a
model example. In 1960, its CC mortality rate was 5/
100,000 women [12]. At that time, Finland introduced
an organised screening programme for CC, which led to
a steep decrease in the rate by 1973, when it was below 1/
100,000 and has remained at that level since then [12]. In
these countries, introduction of vaccination againstHPV is the only way to further decrease the mortality
level in the future, provided that the vaccines are prev-
alent and the appropriate percentage of a given popu-
lation is vaccinated [6]. The rate of change in mortality is
less relevant at the levels around and less than 1/100,000,
because minor fluctuations, insignificantly or not re-
flected in the trend change, are present.
The second group comprises those countries in which
CC mortality is decreasing, but the epidemiological
transition has not been completed yet. It includes East-
Central European countries, where a gradual decrease of
the CC mortality trend has been observed since the ‘90s.
Moreover, if the rate of decline continues in Poland and
Slovenia, their CC mortality will be brought under
control. The third group comprises countries with an
adverse pattern of the epidemiological transition, which
concerns Belarus and Latvia. In their cases, an increase
in CC mortality is observed.
The aforementioned patterns of epidemiological
transition have various reasons. In EU15 Member
States, where screening programmes for CC have been
Fig. 2. (continued).
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change in the trend or intensification of the downward
trend was usually preceded by implementing such pro-
grammes. Moreover, stable political situation, which
has been observed over recent decades, has turned these
programmes into an integral part of health care systems
in these countries. The transformation that underwent in
East-Central European countries after 1990 marked the
beginning of health-related changes. In the Soviet
Union, the health care system was based on the Sie-
maszko’s model. This centralised health care system
meant a widespread and state-funded access to medical
care and its priority was to create an effective model ofcare for mother and child. Access to gynaecological
healthcare became widespread and annual preventive
visits became compulsory for all women. Because of the
fact that pap smear tests constituted an integral part of
the examination [13,16], CC mortality rate in former
Soviet Union countries was low and amounted to, for
example, 2.08/100,000 in Latvia or 2.63/100,000 in
Belarus. Thus, the epidemiological situation in these
countries was close to controlled in 1990. Higher mor-
tality rates were observed in the countries not belonging
to the Soviet Union (Poland, Hungary, Romania,
Bulgaria, Czech Republic, Slovakia and Slovenia).
These countries pursued a partly independent health
C. Wojtyla et al. / European Journal of Cancer 126 (2020) 56e64 63policy. After 1990, the situation changed in all East-
Central European countries. In some of them, for
example in Poland, although no organised early detec-
tion screening programmes for CC were organised,
opportunistic screening with well-functioning labora-
tory base and access to professionals was present. As a
result, CC mortality rates began to fall in these countries
and implementation of such programmes accelerated the
rate of decline. In other countries, for example in Latvia
and Belarus, abandoning obligatory preventive gynae-
cological visits has led to losing control over the epide-
miological situation and an increase in CC mortality
among women. The situation in these countries has not
been brought under control since then.
An aim of screening is not only to prevent mortality
due to CC, but also to minimize morbidity. The analysis
of incidence rates over recent years reveals that the sit-
uation in Europe has not changed significantly. Ac-
cording to the GLOBOCAN report of 2002, CC
incidence rate in Europe was 11.05/100,000 women at
that time [17], whereas in 2018, it was 11.2/100,000
women [1]. Considerable differences are, however,
observed between particular European regions. Higher
rates are observed in Eastern European countries (16.0/
100,000 women) and lower ones in Western Europe (6.8/
100,000 women) [1]. Lower incidence rates are observed
in the EU countries compared to other countries in
Europe. However, differences between old and new EU
members are visible [17]. Currently, downward trends in
CC morbidity are observed in almost all East-Central
European countries, with the exception of Latvia,
Belarus and Ukraine [18].
5. Conclusions
A decline in CC mortality has been observed in most
European countries over the last decades. However, there
are huge disproportions with regard to the mortality and
its trends between individual countries. Those differences
are particularly pronounced between EU15 Member
States and other European countries. Significant differ-
ences are also observed within the group of Eastern-
Central and Southern European countries. Some of them
have reached the level of control over CC. Others, how-
ever, still have CC mortality rates of 4.5/100,000. It is
essential to introduce well-organised screening pro-
grammes for early detection of CC with coverage of a
correspondingly high percentage of the population,
particularly in East-Central Europe, as well as to introduce
high-coverage HPV vaccination in all European countries.
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